Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis

Siber, George R.; Ambrosino, Donna M.; McIver, James; Ervin, T J; Schiffman, Gerald; Sallan, Stephen E.; Grady, George F.

doi:10.1128/iai.45.1.248-254.1984

Cited by 56 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum from a normal non-vaccinated adult was included in each ELISA run to control for interassay variability. Antibody concentrations in patient samples were expressed relative to a reference adult hyperimmune plasma pool [24]. This plasma pool contains 2648 ng antibody N/ml for serotype 3; 1196 ng antibody N/ml for serotype 4; 539 ng antibody N/ml for group 6; 927 ng antibody N/ml for group 9 and 440 ng antibody N/ml for group 19 [24].…”

Section: Anti-capsular Polysaccharide Antibody Assaysmentioning

confidence: 99%

“…Antibody concentrations in patient samples were expressed relative to a reference adult hyperimmune plasma pool [24]. This plasma pool contains 2648 ng antibody N/ml for serotype 3; 1196 ng antibody N/ml for serotype 4; 539 ng antibody N/ml for group 6; 927 ng antibody N/ml for group 9 and 440 ng antibody N/ml for group 19 [24]. Antibody concentrations in the plasma pool were assigned 100 U/ml (100%) for each isotype and each serotype.…”

Section: Anti-capsular Polysaccharide Antibody Assaysmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and immunological evaluation of patients with mild IgG1 deficiency

Kessel

Horikx

Houte

et al. 1999

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYSerum IgG subclass concentrations were determined in patients visiting, the pulmonology out-patient clinic with chronic respiratory tract problems. A total of 24 patients with a serum IgG1 concentration < 4·9 g/l (i.e. below the reference range) and normal values for IgG2, IgM and IgA were included. Patients with a selective IgG1 deficiency were vaccinated with a 23-valent pneumococcal polysaccharide vaccine. There were nine patients with a poor antibody response to pneumococcal capsular polysaccharide antigens. Responsiveness to protein antigens was intact in all patients. Patients with pneumonia showed a significantly lower anti-polysaccharide response in the IgG2 subclass than patients without pneumonia. Patients with recurrent sinusitis showed a significantly lower response in the IgA isotype after vaccination with pneumococcal polysaccharide vaccine compared with non-sinusitis patients. It can be concluded that patients with recurrent sinopulmonary infections and a mild IgG1 subclass deficiency have an impaired IgG1 anti-polysaccharide response, which can extend to decreased IgG2 and IgA anti-polysaccharide responses.

show abstract

Section: Anti-capsular Polysaccharide Antibody Assaysmentioning

confidence: 99%

Section: Anti-capsular Polysaccharide Antibody Assaysmentioning

confidence: 99%

Clinical and immunological evaluation of patients with mild IgG1 deficiency

Kessel

Horikx

Houte

et al. 1999

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…The reaction was stopped with 100 /il 2 N H1SO4, Optical density was measured on a Titertek FLISA reader at 450 nm. An anti-PRP hyperimmune serum (containing 32,5 /ig specific antibody ml [25]) was used as a standard. The standard was assigned arbitrarily to a level of lOO",.…”

Section: Methodsmentioning

confidence: 99%

In Vitro Activation of Human T Lymphocytes byHaemophilus influenzaeTypebCapsular Polysaccharides

Peeters

Tenbergen-Meekes

Heijnen³

et al. 1992

Scand J Immunol

View full text Add to dashboard Cite

Polyribosilribitolphosphate (PRP), the capsular polysaccharide from Haemophilus influenzae type b, is a T-cell-independent type 2 antigen. In vitro culture of adult peripheral blood T cells with 15 micrograms/ml PRP leads to induction of interleukin-2 receptor (IL-2R) expression on up to 10% of T cells. These cells are CD4+ and carry the alpha beta T-cell receptor. PRP, at concentrations above 1-5 micrograms/ml, can also induce in vitro proliferation of both adult and neonatal T cells. We conclude that PRP acts as a human T-cell mitogen. The in vitro proliferative response as well as IL-2R expression was studied in T cells derived from adults after vaccination with native PRP, with PRP conjugated to a carrier protein, or with diphtheria toxoid. Vaccination with conjugated PRP decreased the doses of PRP required for in vitro induction of IL-2R expression and T-cell proliferation. This indicates that vaccination with PRP conjugated to a carrier protein improves the in vitro T-cell response to PRP activation.

show abstract

“…However, the field was not completely abandoned for meningococcal disease, although greatly restricted to experimental research and isolated clinical experiences. [143][144][145][146][147] Passive antibody therapy for infectious diseases then became limited to infections not treated with antibiotics, such as the treatment and prevention of hepatitis B virus, rabies virus, respiratory syncytial virus, Clostridium tetani, Clostridium botulinum, anthrax, Clostridioides difficile colitis, vaccinia virus, echovirus, and enterovirus. 148 However, looming threats in the field of infectious diseases have made the scientific community turn its sight back to the use of antibodies for therapeutic use.…”

Section: Back To the Future: Antibodies For Infectious Disease Therapymentioning

confidence: 99%

Standing on the shoulders of giants: two centuries of struggle against meningococcal disease

Domingo

Pomar

Mauri

et al. 2019

The Lancet Infectious Diseases

View full text Add to dashboard Cite

Meningococcal disease was first clinically characterised by Gaspard Vieusseux in 1805, and its causative agent was identified by Anton Weichselbaum in 1887, who named it Diplococcus intracellularis menigitidis. From the beginning, the disease was dreaded because of its epidemic nature, predilection for previously healthy children and adolescents, and high mortality. In the last decade of the 19th century, the concept of serum therapy for toxin-related bacterial diseases was identified. This concept was applied to meningococcal disease therapy, in an independent way, by Wilhelm Kolle, August von Wasserman, and Georg Jochmann in Germany, and Simon Flexner in the USA, resulting in the first successful approach for the treatment of meningococcal disease. During the first three decades of the 20th century, serum therapy was the standard treatment for meningococcal disease. With the advent of sulphamides first and then antibiotics, serum therapy was abandoned. The great challenges that infectious diseases medicine is facing and the awaiting menaces in the future in terms of increasing antibiotic resistance, emergence of new pathogens, and re-emergence of old ones without effective therapy, make passive immunotherapy a promising tool. Acknowledging the achievements of our predecessors might teach us some lessons to bring light to our future. e285 www.thelancet.com/infection Vol

show abstract

Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis

Cited by 56 publications

References 32 publications

Clinical and immunological evaluation of patients with mild IgG1 deficiency

Clinical and immunological evaluation of patients with mild IgG1 deficiency

In Vitro Activation of Human T Lymphocytes byHaemophilus influenzaeTypebCapsular Polysaccharides

Standing on the shoulders of giants: two centuries of struggle against meningococcal disease

Contact Info

Product

Resources

About